SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Sorrento
Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced that
it has completed the construction of an extensive library of
full-length, fully human monoclonal antibodies (mAbs). Initial
analysis indicates a potential diversity of more than one trillion
unique mAbs. The company believes this makes its library the
largest full-length, fully human antibody library available for
drug discovery and development partnerships. Importantly, Sorrento
Therapeutics' proprietary technologies generate antibodies that are
unencumbered by third-party royalty obligations placed on
conventional antibody discovery technologies.
"We believe Sorrento Therapeutics has one of the strongest
antibody development platforms available. Industry-leading library
diversity and the immediate availability of full-length antibodies
offer rapid discovery and development timelines. Our proprietary
technologies are designed to efficiently identify optimal antibody
candidates against potentially any disease target," said Antonius
Schuh, Ph.D., chairman and chief executive officer of Sorrento
Therapeutics.
Sorrento Therapeutics' proprietary mammalian display system
enables the expression and isolation of full-length human
antibodies. In contrast, antibody libraries displayed in phage or
yeast systems typically generate antibody fragments, which require
further configuration into full-length antibodies for therapeutic
development. Sorrento Therapeutics uses fluorescence-activated cell
sorting (FACS) to rapidly identify high-affinity antibody
candidates from its library for immediate downstream
development.
The extensive diversity of Sorrento Therapeutics' library of
complete antibodies increases the likelihood of identifying
candidates with optimal biological activity against validated
disease targets. Sorrento Therapeutics' patented technology for the
amplification and enrichment of the immunoglobulin variable domain
sequences applies ribonucleic acid (RNA) transcription to ensure
high representation of the vast diversity of the immunoglobulin
gene repertoire. The library was created using an input of
antibody-generating source cells from approximately 600 donors and
covers all major classes of immunoglobulins (i.e. IgM, IgG1 - 4,
IgA, IgD and IgE).
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a development-stage
biopharmaceutical company focused on applying its proprietary
technology platform for the discovery and development of human
therapeutic antibodies for the treatment of a variety of disease
conditions, including cancer, inflammation, metabolic disease and
infectious disease.
Forward-Looking Statements
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include statements about the potential diversity of more than one
trillion unique mAbs and whether the diversity will increase the
likelihood of identifying candidates with optimal biological
activity against validated disease target. Risks and uncertainties
include those risks set forth in Sorrento's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Sorrento's judgment as of the date of this
release. Sorrento disclaims, however, any intent or obligation to
update these forward-looking statements.
www.sorrentotherapeutics.com
SOURCE Sorrento Therapeutics, Inc.